Efficacy and safety of percutaneous computed tomography-guided microwave ablation for colorectal cancer, oligometastatic liver-only disease: a single center's experience.
Colorectal cancer
hepatic metastases
microwave ablation
Journal
Annals of gastroenterology
ISSN: 1108-7471
Titre abrégé: Ann Gastroenterol
Pays: Greece
ID NLM: 101121847
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
02
2020
accepted:
26
06
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
9
1
2021
Statut:
ppublish
Résumé
We retrospectively evaluated the effectiveness and safety of computed tomography-guided percutaneous microwave ablation (MWA) of metastatic liver disease in terms of 5-year overall survival and 5-year disease-free survival. Institutional database research identified 32 colorectal cancer patients with oligometastatic liver-only disease who underwent percutaneous computed tomography-guided MWA. Contrast-enhanced computed tomography or magnetic resonance imaging was used for post-ablation follow up. Patient and tumor characteristics, MWA technique and complications were evaluated. In addition, the 5-year overall survival, the 5-year disease-free survival, and the potential factors affecting the survival of these patients were analyzed. Mean patient age was 72 years (male: female 21:11). In total 58 lesions were treated in 45 ablation sessions. Average lesion size was 2 cm (range 0.8-3.9 cm). The primary tumor for the majority of patients was in the colon (n=27), while in 5 patients it was located in the rectum. The majority of patients had 1 liver metastasis (n=16), 11 patients had 2, 4 patients had 3, and 1 patient had 4. Primary local tumor control was achieved in 91.3% (53/58) of the ablated lesions. Overall survival at 1, 3 and 5 years was 96.8%, 68.7% and 34.3%, respectively. Computed tomography-guided percutaneous MWA for metastatic liver-only disease in oligometastatic patients is a feasible, safe and effective therapy with satisfactory long-term survival rates.
Sections du résumé
BACKGROUND
BACKGROUND
We retrospectively evaluated the effectiveness and safety of computed tomography-guided percutaneous microwave ablation (MWA) of metastatic liver disease in terms of 5-year overall survival and 5-year disease-free survival.
METHODS
METHODS
Institutional database research identified 32 colorectal cancer patients with oligometastatic liver-only disease who underwent percutaneous computed tomography-guided MWA. Contrast-enhanced computed tomography or magnetic resonance imaging was used for post-ablation follow up. Patient and tumor characteristics, MWA technique and complications were evaluated. In addition, the 5-year overall survival, the 5-year disease-free survival, and the potential factors affecting the survival of these patients were analyzed.
RESULTS
RESULTS
Mean patient age was 72 years (male: female 21:11). In total 58 lesions were treated in 45 ablation sessions. Average lesion size was 2 cm (range 0.8-3.9 cm). The primary tumor for the majority of patients was in the colon (n=27), while in 5 patients it was located in the rectum. The majority of patients had 1 liver metastasis (n=16), 11 patients had 2, 4 patients had 3, and 1 patient had 4. Primary local tumor control was achieved in 91.3% (53/58) of the ablated lesions. Overall survival at 1, 3 and 5 years was 96.8%, 68.7% and 34.3%, respectively.
CONCLUSION
CONCLUSIONS
Computed tomography-guided percutaneous MWA for metastatic liver-only disease in oligometastatic patients is a feasible, safe and effective therapy with satisfactory long-term survival rates.
Identifiants
pubmed: 33414623
doi: 10.20524/aog.2020.0545
pii: AnnGastroenterol-34-61
pmc: PMC7774662
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61-67Informations de copyright
Copyright: © 2021 Hellenic Society of Gastroenterology.
Déclaration de conflit d'intérêts
Conflict of Interest: None
Références
Br J Surg. 2010 Mar;97(3):366-76
pubmed: 20101645
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7
pubmed: 15166961
Onco Targets Ther. 2016 Feb 25;9:937-43
pubmed: 26955286
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Ann Surg. 2005 Aug;242(2):158-71
pubmed: 16041205
J Gastrointest Surg. 2006 Jan;10(1):86-94
pubmed: 16368496
Eur J Cancer. 2006 Sep;42(14):2212-21
pubmed: 16904315
Cardiovasc Intervent Radiol. 2008 Sep-Oct;31(5):948-56
pubmed: 18506519
J Gastrointest Surg. 2008 Nov;12(11):1967-72
pubmed: 18688683
Eur Radiol. 2009 May;19(5):1206-13
pubmed: 19137310
Oncol Lett. 2014 Jul;8(1):323-326
pubmed: 24959270
J Surg Oncol. 2015 Mar 15;111(4):410-3
pubmed: 25557924
Cardiovasc Intervent Radiol. 2017 Aug;40(8):1141-1146
pubmed: 28584945
Gastroenterol Clin Biol. 2008 Apr;32(4):390-400
pubmed: 18406091
JAMA Surg. 2013 Jul;148(7):597-601
pubmed: 23699996
J Vasc Interv Radiol. 2010 Aug;21(8 Suppl):S192-203
pubmed: 20656229
Ann Surg. 2002 Jun;235(6):759-66
pubmed: 12035031
Radiology. 2012 Dec;265(3):958-68
pubmed: 23091175
Hepatogastroenterology. 2014 Mar-Apr;61(130):436-41
pubmed: 24901157
Eur J Cancer. 2014 Mar;50(5):912-9
pubmed: 24411080
Ann Surg. 2014 Jun;259(6):1195-200
pubmed: 24096760
Ann Surg Oncol. 2011 Jul;18(7):1947-54
pubmed: 21399885
Onco Targets Ther. 2019 Aug 13;12:6407-6438
pubmed: 31496742
Ann Surg. 2008 Mar;247(3):451-5
pubmed: 18376189
Ann Surg. 2007 Oct;246(4):559-65; discussion 565-7
pubmed: 17893492
Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50
pubmed: 15319715
Ann Oncol. 2012 Oct;23(10):2619-2626
pubmed: 22431703
Br J Radiol. 2011 Jun;84(1002):556-65
pubmed: 21159807
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787